Navigation Links
Isis Reports Preclinical Data Supporting Liver Safety of ISIS 301012
Date:10/6/2007

ion led to compensatory changes in liver fat metabolism including reduced fat production and increased fat breakdown. These changes were documented in metabolic indicators measured in the blood serum and were accompanied by consistent changes in liver gene expression profiles. Having now developed the appropriate tests and demonstrated that serum metabolites are relevant indicators of liver fat metabolism in preclinical studies, Isis plans to incorporate similar measurements in its future clinical trials of ISIS 301012.

ABOUT ISIS 301012 AND CHOLESTEROL

ISIS 301012 is a second-generation antisense drug that reduces the production of apoB-100, a protein critical to the synthesis and transport of "bad" cholesterol and a target that has proved to be undruggable using traditional, small-molecule approaches. Cholesterol can be carried in the bloodstream in a variety of forms, with high-density lipoprotein, or HDL-C, being the good form, and low-density lipoproteins, or LDL-C, and very low-density lipoproteins, or VLDL-C, being bad forms directly involved in heart disease. Collectively, LDL-C, VLDL-C, and other bad forms of cholesterol are referred to as "non-HDL-C." The lowering of non-HDL-C is a key component in the prevention and management of cardiovascular disease. Isis plans to develop ISIS 301012 as the drug of choice for patients who are unable to achieve target cholesterol levels with statins alone or who are intolerant of statins. Isis has selected 200 mg/week as its development dose for future studies, including the registration studies for FH and the long-term coadministration study planned for patients with routine high cholesterol, both expected to begin this year.

Conference Call Information

At 8:00 a.m. Eastern Time Monday, October 8, Isis will conduct a live webcast conference call to discuss ISIS 301012 results. Interested parties may access the webcast at http://www.isispharm.com'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: ... immune therapies for operable and inoperable solid tumor cancers, announced ... the 7 th Annual Phacilitate Immunotherapy Forum in ... at Phacilitate will take place on January 26 at 10:30 ...
(Date:1/23/2015)... Fla. and DUBLIN , Jan. ... the agreement with KRS Global Biotechnology, Inc. for the compounding, ... be compounded for shipment in the United States ... FDA approved Outsourcing Facility capable of compounding naltrexone tablets in ...
(Date:1/23/2015)...  HyGreen, Inc., a leader in hand hygiene monitoring, today ... a subsidiary of Ascendis Health Limited, in ... hundreds of millions of patients around the world are ... from patient to patient via the unwashed hands of ...
Breaking Medicine Technology:NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4HyGreen Partners with RCA Medical in Johannesburg, South Africa 2
... 25, 2011 Hologic , Inc. (Hologic ... developer, manufacturer and supplier of premium diagnostics, medical imaging systems ... Drug Administration (FDA) has cleared two Hologic magnetic resonance imaging ... channel Breast Coil for several Siemens platforms. ...
... Masimo (NASDAQ: MASI ) today ... October 1, 2011. Masimo’s total third ... compared to $101.0 million for 2010’s third quarter.  The ... million, compared to $88.8 million for the third quarter ...
Cached Medicine Technology:Hologic Adds New Products to Its MRI Solutions Portfolio 2Hologic Adds New Products to Its MRI Solutions Portfolio 3Masimo Reports Third Quarter 2011 Financial Results 2Masimo Reports Third Quarter 2011 Financial Results 3Masimo Reports Third Quarter 2011 Financial Results 4Masimo Reports Third Quarter 2011 Financial Results 5Masimo Reports Third Quarter 2011 Financial Results 6Masimo Reports Third Quarter 2011 Financial Results 7Masimo Reports Third Quarter 2011 Financial Results 8Masimo Reports Third Quarter 2011 Financial Results 9
(Date:1/22/2015)... Liberty University has received accreditation for its resident ... Council for Accreditation of Counseling & Related Educational Programs ... for Counseling & Family Studies , is under the leadership ... School of Behavioral Sciences. Prior to the formation of the ...
(Date:1/22/2015)... 22, 2015 Woodloch Pines, an all-inclusive ... selected by TripAdvisor as the number one best large hotel ... in the world for their annual Travelers’ Choice Awards. ... . The website is home to millions of unbiased and ...
(Date:1/22/2015)... VogueQueen is a seasoned and trusted leader ... designers are thrilled to have it lead the wedding dress ... collection of prom dresses for the global market. , “The ... vision and he focuses on continuing the goal of operational ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota ... it means to “Live Fearless.” , The “Faces ... their stories about how they or someone they know has ... living in the moment. By telling these types of stories ...
(Date:1/22/2015)... 2015 Juvent Sports ( http://www.juventsports.com ) ... PGA Merchandise Show to bestow a Juvent Sports Achievement ... golfer, Arlene McKitrick. The award commemorated and congratulated McKitrick ... win. She won her first amateur tournament in 1979 ...
Breaking Medicine News(10 mins):Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3
... of a molecular community in brain cells of mammals ... of new drugs. Researchers from Mount Sinai School // ... latest issue of journal Science. , ,The study ... within these communities enable groups of molecules and proteins ...
... the spice turmeric its yellow color, has come under ... its cancer-fighting abilities // . ,Researchers say ... block a key protein associated with esophageal cancer, known ... “ a shot in the arm for research,” ...
... time for meditation, yoga or even a trip to ... very compact these days. Thanks to the Chocolate-coated stress ... soon. ,The chocolate-like product comprises various nutraceutical herbs ... been developed by National Botanical Research Institute (NBRI), Lucknow., ...
... A protein that protects the body from tissue damage has ... protein helps the body's healthy cells survive the effects of ... found to encourage the growth of tumors in mice following ... urethane, a lung-specific carcinogen, on two sets of mice, which ...
... Mark A. Fishel, M.D., from the University of Washington, ... increase in Alzheimer’s disease. Moderately elevated levels of ... // in plasma and in cerebrospinal fluid and these ... was conducted in 16 healthy older adults ranging in ...
... from UCLA had found out that a deficient gene ... enzyme in the vision cycle that causes congenital blindness ... disease // called Leber congenital amaurosis is published in ... suggest that replacement of RPE65, which is lacking in ...
Cached Medicine News:Health News:The effects of Curcumin: a natural pigment in turmeric explored for its anti-cancer properties 2Health News:Enzyme Responsible For Congenital Blindness 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: